Early-oral antibiotics showed safety superiority and efficacy equivalence versus IV-only in patients requiring prolonged therapy
This randomized controlled trial enrolled patients who required two or more weeks of IV antibiotics for all but central nervous system infections. The study took place across five hospitals in a rural health system. Participants were assigned to an early-oral group or a control group receiving IV-only therapy.
The early-oral group showed a significantly lower adverse event rate of 3.2% versus 6.5% in the control group. The P value for this difference was .02. The cumulative hazard for the first study-related adverse event was also lower in the early-oral group with a hazard ratio of 0.24. The 95% confidence interval for this hazard ratio ranged from .08 to .75, with a P value of .01.
Therapeutic efficacy was reported as equivalent between the groups. No specific p-values or confidence intervals were reported for efficacy outcomes. A significant positive association was found between the COPAT:OPAT program consult ratio and cumulative enrollment, with an R2 value of 0.54 and a P value less than .001.
Safety data indicated significantly lower adverse event rates in the early-oral group. Information regarding serious adverse events, discontinuations, and tolerability was not reported. The study did not report funding sources or conflicts of interest. Implementation of the COPAT Trial accelerated practice transformation in the setting.